Pulmonary Embolism Industry Outlook 2025-2029: Market Set to Cross $3.63 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

How Large Will the Pulmonary Embolism Market Size By 2025?
The market size for pulmonary embolism has seen a swift increase in the last few years. It is set to expand from $2.03 billion in 2024 to $2.27 billion in 2025, with a compound annual growth rate (CAGR) of 11.9%. The rise during the historical period is linked to factors such as anticoagulant therapies, research and clinical trials, increased knowledge about pulmonary embolism, and VTE prophylaxis.

How Big Is the Pulmonary Embolism Market Size Expected to Grow by 2029?
The market size for pulmonary embolism is set to experience an accelerated expansion in the coming years, with projected growth to $3.63 billion by 2029, representing a compound annual growth rate (CAGR) of 12.5%. This expansion during the forecast period can be linked to strategies such as targeted therapies, telemedicine and remote patient monitoring, initiatives focused on health equality, and international health programmes. Emerging trends set to shape the industry during this period include the incorporation of artificial intelligence in diagnosis, new types of anticoagulants, response teams specialized in pulmonary embolism, and a growing focus on patient-oriented care.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Which Key Market Drivers Powering Pulmonary Embolism Market Expansion and Growth?
The prevalence of blood clots is on the rise and is predicted to boost the pulmonary embolism market's growth. A blood clot or thrombus is a semi-solid or gel-like mass that forms inside a blood vessel. These clots increase the likelihood of pulmonary embolism by hindering the blood flow to the lungs. These clots usually create a blockage in the deep veins of the legs, thereby raising the risk of pulmonary embolism. For example, as per an article by Gavi, the Vaccine Alliance, a global organisation aiming to improve new and underused vaccines' access for children in April 2022, scientists found a 33-fold increase in the possibility of fatal clots in the lungs and a five-fold rise in deep vein thrombosis risk within 30 days of COVID-19 exposure. Hence, the growing incidence of blood clots is leading to an expansion in the pulmonary embolism market. A rise in cancer cases is also expected to promote the growth of the pulmonary embolism market. Cancer is a collection of diseases marked by uncontrolled and abnormal cell growth. A higher prevalence of cancer increases the risk of blood clots like pulmonary embolism in cancer patients, thus heightening the need for diagnostic procedures and treatments, including specific drugs. In January 2024, for instance, the American Cancer Society, a non-profit cancer advocacy organisation based in the US, reported a 2.19% growth in cancer cases, increasing to 2,001,140 from 1,958,310 in 2023. Therefore, the escalating incidence of cancer is influencing the expansion of the pulmonary embolism market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Pulmonary Embolism Market?
Leading enterprises in the pulmonary embolism market are concentrating on the creation of innovative products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter, with the aim of maintaining a competitive edge. For instance, in June 2023, Inari Medical Inc., a medical device company based in the United States, introduced the Triever16 Curve catheter and the RevCore thrombectomy catheter. The cutting-edge Triever16 Curve catheter is specifically engineered for peripheral thrombectomy and pulmonary embolism operations. It boasts exceptional trackability, a pre-defined curve for concentrated aspiration, and a distinctive design permitting easy entry to larger, more powerful 20F or 24F catheters. The RevCore thrombectomy catheter, on the other hand, is intended to treat venous in-stent thrombosis. It is a mechanical thrombectomy tool that employs a nitinol basket to ensnare and extract blood clots. These catheters also provide enhanced safety and effectiveness in pulmonary embolism procedures.

What Are the Emerging Segments in the Pulmonary Embolism Market?
The pulmonary embolism market covered in this report is segmented -

1) By Treatment: Medications, Mechanical Devices, Other Treatments
2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis
3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Medications: Anticoagulants, Thrombolytics
2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy
3) By Other Treatments: Surgical Embolectomy, Supportive Care

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

Who Are the Global Leaders in the Pulmonary Embolism Market?
Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

Which are the Top Profitable Regional Markets for the Pulmonary Embolism Industry?
North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.